FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2220809980> ?p ?o ?g. }

• W2220809980 endingPage "1182" @default.
• W2220809980 startingPage "1172" @default.
• W2220809980 abstract "BACKGROUND: Type 2 diabetes mellitus (T2DM) is a progressive disease. Despite starting with single oral antidiabetes drug (OAD) therapy and then adding OAD(s), most patients eventually require insulin therapy to achieve and maintain glycemic control. The timely initiation of insulin therapy could help patients with T2DM whose glycemic control is not adequately maintained using OADs alone. OBJECTIVE: To describe and compare baseline characteristics and assess real-world health outcomes associated with initiating basal insulin after 1 OAD, 2 OADs, or ≥ 3 OADs among T2DM patients. METHODS: Data were analyzed from adult T2DM patients in a U.S. managed care claims database (IMPACT) who initiated a basal insulin (from January 1, 2001, to December 31, 2011) with continuous health plan enrollment for 6 months before (baseline) and 12 months after (follow-up) insulin initiation and who had at least 1 OAD prescription. Outcome measures according to the number of OADs used were (a) treatment discontinuation, (b) glycated hemoglobin (A1c) levels, (c) proportion of patients experiencing hypoglycemia, (d) health care resource utilization, and (e) costs. RESULTS: Data from 71,988 patients were included (1 OAD: 19,168 patients [26.6%]; 2 OADs: 29,112 [40.4%]; and ≥ 3 OADs: 23,708 [32.9%]). All baseline characteristics, except nephropathy, were significantly different across the 3 groups. At baseline, when compared with the 1 OAD or 2 OADs groups, the ≥ 3 OADs group was less likely to be female or have macrovascular disease and had experienced fewer hypoglycemic events and hospitalization as well as lower costs. At follow-up, treatment discontinuation rates were 36.0%, 27.6%, and 21.4% for the 1 OAD, 2 OADs, and ≥ 3 OADs groups, respectively. A1c reduction was −1.33%, −1.05%, and −0.86%, respectively. The proportion of patients experiencing any hypoglycemia was 4.7%, 3.8%, and 3.3% at baseline; and 3.7%, 3.5%, and 3.1% at follow-up for the 1 OAD, 2 OADs, and ≥ 3 OADs groups, respectively. In all 3 groups, health care costs decreased compared with baseline, particularly in the 1 OAD and 2 OADs groups, with decreased inpatient costs offsetting increased drug costs. CONCLUSIONS: This real-world analysis shows that there are significant baseline differences in patients with T2DM on 1 OAD, 2 OADs, or ≥ 3 OADs when adding insulin therapy. All 3 groups had significant improvements in clinical and economic outcomes compared with baseline, yet at different magnitudes. These data contribute to a growing body of evidence supporting the timely initiation of insulin therapy for T2DM patients not maintaining glycemic control with OADs. DISCLOSURES: This study was funded by Sanofi U.S. Levin serves on an advisory panel for Sanofi U.S. Zhou, Gill, and Wei are employees of Sanofi U.S. Zhou developed the study design and methodology, collected the data, provided statistical and analytic reflections of the data, and drafted the study reports. Wei codeveloped the study design, researched data, contributed to discussion, and reviewed the manuscript. Levin and Gill provided clinical insights for the study design and data interpretation, contributed to discussion, and reviewed the manuscript. All authors had full access to all the data in the study. Zhou is the guarantor of this work and, as such, takes responsibility for the integrity of the data and the accuracy of the data analysis." @default.
• W2220809980 created "2016-06-24" @default.
• W2220809980 creator A5017602024 @default.
• W2220809980 creator A5022873764 @default.
• W2220809980 creator A5056499278 @default.
• W2220809980 creator A5058465669 @default.
• W2220809980 date "2015-12-01" @default.
• W2220809980 modified "2023-09-30" @default.
• W2220809980 title "Health Outcomes Associated with Initiation of Basal Insulin After 1, 2, or ≥ 3 Oral Antidiabetes Drug(s) Among Managed Care Patients with Type 2 Diabetes" @default.
• W2220809980 cites W126610468 @default.
• W2220809980 cites W1970097242 @default.
• W2220809980 cites W1975588287 @default.
• W2220809980 cites W1977389382 @default.
• W2220809980 cites W1997175144 @default.
• W2220809980 cites W2001756472 @default.
• W2220809980 cites W2008603972 @default.
• W2220809980 cites W2023984564 @default.
• W2220809980 cites W2040045465 @default.
• W2220809980 cites W2041064480 @default.
• W2220809980 cites W2041901656 @default.
• W2220809980 cites W2060255598 @default.
• W2220809980 cites W2072239150 @default.
• W2220809980 cites W2076219300 @default.
• W2220809980 cites W2078089300 @default.
• W2220809980 cites W2078806330 @default.
• W2220809980 cites W2079335866 @default.
• W2220809980 cites W2099102828 @default.
• W2220809980 cites W2101244337 @default.
• W2220809980 cites W2102076191 @default.
• W2220809980 cites W2113322194 @default.
• W2220809980 cites W2113519759 @default.
• W2220809980 cites W2114117378 @default.
• W2220809980 cites W2114702224 @default.
• W2220809980 cites W2132662207 @default.
• W2220809980 cites W2138016702 @default.
• W2220809980 cites W2146681672 @default.
• W2220809980 cites W2148392045 @default.
• W2220809980 cites W2153449155 @default.
• W2220809980 cites W2171294019 @default.
• W2220809980 cites W2285353026 @default.
• W2220809980 cites W2302447233 @default.
• W2220809980 cites W2337454357 @default.
• W2220809980 cites W2474835 @default.
• W2220809980 cites W2510708214 @default.
• W2220809980 cites W2554729258 @default.
• W2220809980 cites W2586645431 @default.
• W2220809980 cites W4234113403 @default.
• W2220809980 cites W4252937268 @default.
• W2220809980 doi "https://doi.org/10.18553/jmcp.2015.21.12.1172" @default.
• W2220809980 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26679966" @default.
• W2220809980 hasPublicationYear "2015" @default.
• W2220809980 type Work @default.
• W2220809980 sameAs 2220809980 @default.
• W2220809980 citedByCount "10" @default.
• W2220809980 countsByYear W22208099802016 @default.
• W2220809980 countsByYear W22208099802017 @default.
• W2220809980 countsByYear W22208099802018 @default.
• W2220809980 countsByYear W22208099802020 @default.
• W2220809980 crossrefType "journal-article" @default.
• W2220809980 hasAuthorship W2220809980A5017602024 @default.
• W2220809980 hasAuthorship W2220809980A5022873764 @default.
• W2220809980 hasAuthorship W2220809980A5056499278 @default.
• W2220809980 hasAuthorship W2220809980A5058465669 @default.
• W2220809980 hasBestOaLocation W22208099801 @default.
• W2220809980 hasConcept C126322002 @default.
• W2220809980 hasConcept C134018914 @default.
• W2220809980 hasConcept C177713679 @default.
• W2220809980 hasConcept C194828623 @default.
• W2220809980 hasConcept C2426938 @default.
• W2220809980 hasConcept C2777180221 @default.
• W2220809980 hasConcept C2777538456 @default.
• W2220809980 hasConcept C2778715236 @default.
• W2220809980 hasConcept C2779306644 @default.
• W2220809980 hasConcept C2780473172 @default.
• W2220809980 hasConcept C2780668416 @default.
• W2220809980 hasConcept C2910068830 @default.
• W2220809980 hasConcept C555293320 @default.
• W2220809980 hasConcept C71924100 @default.
• W2220809980 hasConcept C98274493 @default.
• W2220809980 hasConceptScore W2220809980C126322002 @default.
• W2220809980 hasConceptScore W2220809980C134018914 @default.
• W2220809980 hasConceptScore W2220809980C177713679 @default.
• W2220809980 hasConceptScore W2220809980C194828623 @default.
• W2220809980 hasConceptScore W2220809980C2426938 @default.
• W2220809980 hasConceptScore W2220809980C2777180221 @default.
• W2220809980 hasConceptScore W2220809980C2777538456 @default.
• W2220809980 hasConceptScore W2220809980C2778715236 @default.
• W2220809980 hasConceptScore W2220809980C2779306644 @default.
• W2220809980 hasConceptScore W2220809980C2780473172 @default.
• W2220809980 hasConceptScore W2220809980C2780668416 @default.
• W2220809980 hasConceptScore W2220809980C2910068830 @default.
• W2220809980 hasConceptScore W2220809980C555293320 @default.
• W2220809980 hasConceptScore W2220809980C71924100 @default.
• W2220809980 hasConceptScore W2220809980C98274493 @default.
• W2220809980 hasIssue "12" @default.
• W2220809980 hasLocation W22208099801 @default.
• W2220809980 hasLocation W22208099802 @default.
• W2220809980 hasOpenAccess W2220809980 @default.

• next